Payment overview · 2025
General Payments
$610.57
25 reported records · 8 companies
Healthcare provider profile · identity verified
Sangjun Byeon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROWLAND HEIGHTS, CA · NPI 1659574945
Verified facts
What the public records show
CMS Open Payments records show Sangjun Byeon, MD received $610.57 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 53.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $328.97 | 53.9% | 13 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $101.83 | 16.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.97 | 8.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.73 | 6.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.69 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.36 | 3.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.74 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.28 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $610.57 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $167.31 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $145.84 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $101.83 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $69.71 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.73 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 62 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
62 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 162 |
| Metformin Hcl | Metformin Hcl | 382 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 95 |
| Losartan Potassium | Losartan Potassium | 349 | 97 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 251 | 62 |
| Simvastatin | Simvastatin | 203 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 48 |
| Vascepa | Icosapent Ethyl | 136 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 30 |
| Temazepam | Temazepam | 102 | 36 |
| Farxiga | Dapagliflozin Propanediol | 97 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 97 | 28 |
| Januvia | Sitagliptin Phosphate | 91 | 14 |
| Montelukast Sodium | Montelukast Sodium | 88 | 42 |
| Glipizide | Glipizide | 86 | 19 |
| Celecoxib | Celecoxib | 85 | 46 |
| Donepezil Hcl | Donepezil Hcl | 84 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 21 |
| Omeprazole | Omeprazole | 78 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 77 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 66 | 32 |
| Creon | Lipase/Protease/Amylase | 62 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 37 |
| Azithromycin | Azithromycin | 59 | 54 |
| Atenolol | Atenolol | 58 | 13 |
| Finasteride | Finasteride | 55 | 19 |
| Metformin Hcl Er | Metformin Hcl | 55 | 15 |
| Meloxicam | Meloxicam | 52 | 23 |
| Gabapentin | Gabapentin | 50 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 46 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 14 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 31 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 14 |
| Mupirocin | Mupirocin | 27 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | 13 |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Prednisone | Prednisone | 14 | 12 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $610.57 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, JARDIANCE, LINZESS, Repatha, SHINGRIX, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error